Hengrui Pharmaceutical announced that recently, its subsidiaries Shanghai Shengdi Pharmaceutical Co., Ltd. and Suzhou Shengdia Biomedical Co., Ltd. received approval from the State Drug Administration to issue a “Pharmaceutical Clinical Trial Approval Notice” for adbelimab injections and SHR-8068 injections, and will conduct clinical trials in the near future.

Zhitongcaijing · 01/30/2024 08:17
Hengrui Pharmaceutical announced that recently, its subsidiaries Shanghai Shengdi Pharmaceutical Co., Ltd. and Suzhou Shengdia Biomedical Co., Ltd. received approval from the State Drug Administration to issue a “Pharmaceutical Clinical Trial Approval Notice” for adbelimab injections and SHR-8068 injections, and will conduct clinical trials in the near future.
Recently
Symbol
Price
%Change